SPY310.52+2.16 0.70%
DIA257.31-0.56 -0.22%
IXIC10,154.63+95.86 0.95%

Stifel Nicolaus Downgrades Supernus Pharmaceuticals to Hold, Lowers Price Target to $23

Stifel Nicolaus downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Buy to Hold and lowers the price target from $55 to $23.

Benzinga · -

Stifel Nicolaus downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Buy to Hold and lowers the price target from $55 to $23.